Trial Profile
A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Padeliporfin (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- Sponsors Steba Biotech
- 28 Apr 2015 Status changed from suspended to discontinued as per ClinicalTrials.gov record.
- 24 Nov 2014 New trial record